Johnson & Johnson (NYSE:JNJ – Get Free Report) shares rose 2.1% on Tuesday . The company traded as high as $271.91 and last traded at $271.53. Approximately 5,948,628 shares changed hands during trading, a decline of 27% from the average daily volume of 8,178,312 shares. The stock had previously closed at $265.85.
Key Johnson & Johnson News
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Johnson & Johnson renewed its decades-long dividend-raising streak, reinforcing its appeal to income-oriented investors. Recent coverage also highlights JNJ’s history of maintaining dividend growth through recessions, which supports the stock’s defensive reputation. Why Procter & Gamble’s Quieter Dividend Outpaces Johnson & Johnson’s Growth Story
- Positive Sentiment: Johnson & Johnson’s portfolio of stakes in biotechnology and medical-technology companies provides potential longer-term value, with one investment standing out as the largest and most valuable holding. Johnson & Johnson Owns Stakes in 15 Stocks. Here’s the Best of the Bunch.
- Neutral Sentiment: JNJ scheduled its third-quarter results conference call for October 13, giving investors a defined upcoming catalyst. Management will discuss results and answer questions, but the announcement contained no new financial guidance. Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
- Negative Sentiment: Erste Group Bank trimmed its 2026 earnings-per-share forecast to $11.65 from $11.68. The reduction is minor and remains above the broader consensus estimate of $11.61, but it signals limited near-term earnings momentum.
- Negative Sentiment: Coverage comparing JNJ with Procter & Gamble cautions that an upcoming corporate event could complicate Johnson & Johnson’s otherwise impressive dividend-growth story. That creates some uncertainty for investors who prioritize uninterrupted payout growth.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on JNJ shares. Citigroup increased their price target on Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 24th. Scotiabank reaffirmed an “outperform” rating and set a $305.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Johnson Rice restated a “buy” rating on shares of Johnson & Johnson in a report on Monday, August 3rd. Finally, Morgan Stanley lifted their target price on Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $268.22.
Johnson & Johnson Stock Up 2.1%
The business’s 50 day simple moving average is $259.57 and its 200 day simple moving average is $244.17. The company has a market capitalization of $654.36 billion, a PE ratio of 31.46, a price-to-earnings-growth ratio of 2.56 and a beta of 0.24. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.61 EPS for the current year.
Johnson & Johnson Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is 62.11%.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares in the company, valued at $4,367,458. The trade was a 48.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 63,972 shares of company stock worth $16,245,605 in the last quarter. 0.16% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Johnson & Johnson
A number of hedge funds have recently added to or reduced their stakes in JNJ. California State Teachers Retirement System grew its position in Johnson & Johnson by 25,103.8% in the second quarter. California State Teachers Retirement System now owns 943,488,645 shares of the company’s stock worth $239,617,811,000 after acquiring an additional 939,745,213 shares in the last quarter. Auto Owners Insurance Co increased its position in Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after buying an additional 69,108,368 shares during the last quarter. Norges Bank acquired a new position in Johnson & Johnson during the fourth quarter worth $6,924,523,000. Capital World Investors bought a new position in Johnson & Johnson during the fourth quarter valued at about $2,005,942,000. Finally, Jupiter Topco LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $1,967,399,000. Institutional investors and hedge funds own 69.55% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Read More
- Five stocks we like better than Johnson & Johnson
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
